{
  "outcomes_metadata": {
    "timestamp": "2025-09-19T15:06:49.437882",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 32,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "Overall survival (OS; defined as time from randomisation to death from any cause)",
        "Progression-free survival (PFS; defined as time from randomisation until disease progression or death from any cause; may be assessed by independent, blinded review panel per RECIST 1.1 or investigator-assessed)",
        "Event-free survival",
        "Time to progression (TTP)",
        "Time to next treatment (TTNT)",
        "Progression after next line of therapy (PFS2)",
        "Prolonged survival"
      ],
      "response_measures": [
        "Objective response rate (ORR; includes response rates, measured by RECIST 1.1 or RECIST criteria, as evaluated by independent review committee or investigator)",
        "Disease control rate (proportion of patients with complete, partial, or stable disease for at least 5 weeks)",
        "Time to response (time from treatment initiation to first complete or partial response)",
        "Duration of response (DoR; time from first partial or complete response to first relapse or progression per RECIST 1.1 or death from any cause)",
        "Treatment duration (duration of treatment)"
      ],
      "progression_measures": [
        "Sensitivity analysis of progression-free survival (considering initiation of new anti-cancer therapy as a PFS event)"
      ]
    },
    "safety": {
      "adverse_events": [
        "Adverse events (AEs; including all grades and grade â‰¥3, collected according to CTCAE v5.0 or v4.03, or graded by CTCAE; includes specific events: diarrhoea, ALT increase, AST increase, neutropenia, fatigue, febrile neutropenia)",
        "Adverse effects",
        "Side effects",
        "Potential risk of serious side effects on the skin",
        "Tolerability profile",
        "Safety"
      ],
      "serious_events": [
        "Serious adverse events (Grade 3-4)",
        "Serious undesirable effects",
        "Mortality-related toxicity"
      ],
      "discontinuations": [
        "Discontinuation due to adverse events (time from first dose until discontinuation due to AEs)"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "Health-related quality of life (HRQoL; measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires, or EORTC QLQ; includes adjustment for multiplicity in analyses of median survival for certain QoL dimensions)",
        "Patient-reported outcomes (PROMs; including EORTC QLQ)",
        "Quality-adjusted life years (QALYs)",
        "Preservation of quality of life"
      ],
      "functional_status": [
        "Overall condition (Karnofsky or ECOG performance status)",
        "Time to deterioration of overall health status",
        "Time to deterioration of physical functioning"
      ],
      "symptom_measures": [
        "Endpoints on symptomatology and health status",
        "Symptom control"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "Cost-effectiveness (incremental cost-effectiveness ratio, ICER; cost per QALY achieved; modelled as mean overall and progression-free survival, incremental cost-effectiveness ratio)"
      ],
      "utilities": [
        "Utility values in the progression-free health state (visual analogue scale)",
        "Treatment-related disutility for intravenous administration"
      ],
      "resource_utilization": [
        "Resource use estimates"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "Treatment duration (duration of treatment)",
        "Sensitivity analysis of progression-free survival"
      ],
      "biomarkers": [
        "Mutation status determination (KRAS G12C mutation, DNA sequencing or multiplex RT-PCR panel assays)"
      ]
    }
  }
}